| Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2010: ¥1,235,000 (Direct Cost: ¥950,000、Indirect Cost: ¥285,000)
Fiscal Year 2009: ¥1,365,000 (Direct Cost: ¥1,050,000、Indirect Cost: ¥315,000)
|
|---|
| Research Abstract |
Because the combination of bevacizumab and S-1 which was a 5-FU-based anticancer agent which was the molecular target drug of the vascularization repressor showed a significant antitumor effect in the implanted nude mouse of the oral squamous cell carcinoma cell, HSC-2, it was suggested that it was with new Tumor dormancy therapy for oral cancer.
|
